Biomed Lublin to finalize new factory project by the end of 2018

Pharmaceutical company Biomed Lublin wants to complete financing for its new factory, which is valued at PLN 150 million, by the end of this year, company President Marcin Piróg has informed. "We are working on financing the project of the new factory, and we want to finish these issues by the end of this year," said Piróg at a press conference. EU funding should cover up to 60 percent of the project value, with the remaining amount to be contributed by the company through debt financing or bridge financing with the target sale of real estate. Biomed Lublin Wytwórnia Surowic i Szczepionek is a Polish pharmaceutical company operating since 1944. The company deals in the production of medicinal preparations and has been listed on the main WSE market since 2015. Its sales revenues reached PLN 36.34 million in 2016.